The release of Phase 2a trial data is a critical event for biotech companies like Organovo, as it provides investors with insights into the efficacy and safety of a drug candidate. Positive results could significantly boost investor confidence and drive the stock price up, while negative results could have the opposite effect. Given that the news is about a future event, it may lead to increased speculation and trading activity as the release date approaches.